Diagnostic Approach and Management of Bartter Syndrome

Key Diagnostic Features

The clinical presentation of severe hypocalcemia, acute kidney injury (AKI), polyuria, altered sensorium, and hypokalemia in a patient strongly suggests Bartter syndrome, particularly Type 1 or Type 2, which are characterized by salt-losing tubulopathy with these exact electrolyte derangements 1, 2, 3
Polyuria with salt wasting is the hallmark of impaired salt reabsorption in the thick ascending limb of Henle's loop 2, 3
Severe hypokalemia results from increased distal sodium delivery and aldosterone-mediated potassium secretion 1, 4
Hypocalcemia in this context likely represents severe hypomagnesemia, which impairs PTH secretion and causes functional hypocalcemia 5
AKI with polyuria represents the paradoxical combination of volume depletion from salt wasting despite ongoing urinary losses 1, 3

Immediate laboratory assessment should include serum electrolytes with particular attention to chloride, magnesium, and calcium (ionized calcium preferred) 1, 3
Fractional excretion of chloride (typically >0.5% in Bartter syndrome) 3, 4
Urinary calcium-creatinine ratio to distinguish between types (hypercalciuria suggests Type 1 or 2) 1, 3
Acid-base status (hypochloremic metabolic alkalosis expected) 2, 3
Renin and aldosterone levels (hyperreninemic hyperaldosteronism) 2
Renal ultrasound to detect nephrocalcinosis (typical in Types 1 and 2) 1, 3
Genetic testing with a gene panel should be offered to confirm the diagnosis (SLC12A1 for Type 1, KCNJ1 for Type 2), as this has 90-100% analytical sensitivity in children and guides long-term management 1, 3

Severe hypocalcemia requires urgent IV calcium gluconate, but monitor ECG closely as hypocalcemia may paradoxically protect against arrhythmias from severe hypokalemia
Aggressive potassium chloride replacement is essential, using only potassium chloride (not potassium citrate), with doses of 20-60 mEq/day, targeting serum potassium 4.5-5.0 mEq/L 6
Volume resuscitation with normal saline addresses the volume depletion from salt wasting and provides chloride for bicarbonate excretion 6, 4
Magnesium replacement is critical as hypomagnesemia impairs calcium homeostasis and potassium repletion 5

Sodium chloride supplementation (5-10 mmol/kg/day) is the cornerstone of therapy to address the fundamental salt-wasting defect 6, 7
NSAIDs (indomethacin) should be considered for symptomatic patients to inhibit prostaglandin-mediated salt wasting, but must be accompanied by gastric acid suppression 6, 7
Potassium-sparing diuretics (amiloride 2.5-5 mg daily or spironolactone 25-100 mg daily) can help maintain potassium levels, but use cautiously as they may worsen volume depletion despite improving hypokalemia 6, 7

Do not use potassium citrate or other non-chloride potassium salts, as these worsen the metabolic alkalosis that perpetuates potassium wasting 6
Avoid aggressive diuretic therapy - this presentation mimics but is opposite to volume overload conditions requiring diuresis 4
Do not overlook magnesium replacement - hypocalcemia will not correct without addressing concurrent hypomagnesemia 5
Recognize that standard AKI management does not apply - this is volume depletion from salt wasting, not intrinsic renal disease, requiring salt supplementation rather than restriction 1, 3